BioTuesdays

Tag - H.C. Wainwright

Aileron Therapeutics Logo

HCW cuts Aileron Therapeutics PT to $1 from $2

H.C. Wainwright reduced its price target for Aileron Therapeutics (NASDAQ:ALRN) to $1 from $2, but maintained its “buy” rating, after the company reported “underwhelming” interim data from a Phase 1 study in non-small...

Theseus Logo

HCW starts Theseus Pharma at buy; PT $22

H.C. Wainwright launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and price target of $22. The stock closed at $5.20 on June 29. “We believe pan-inhibition could be the key to success in...

Acumen Pharmaceuticals Logo

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

Celularity

HCW starts Celularity at buy; PT $15

H.C. Wainwright initiated coverage of Celularity (NASDAQ:CELU) with a “buy” rating and $15 price target. The stock closed at $3.78 on June 21. Celularity is a clinical-stage biopharmaceutical company focused on...

Pulse Biosciences Logo

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...

Amarin

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

Shattuck Labs

HCW starts Shattuck Labs at buy; PT $28

H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...

Vera-Therapeutics

HCW starts Vera Therapeutics at buy; PT $35

H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...

Syndax Pharma Logo

HCW starts Syndax Pharma at buy; PT $31

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and $31 price target. The stock closed at $17.51 on April 8. Syndax is a clinical-stage biopharmaceutical company focused on...